303 related articles for article (PubMed ID: 28110575)
1. Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth.
Kim HM; Kim SA; Park SB; Cho JH; Song SY
Scand J Gastroenterol; 2017 May; 52(5):577-584. PubMed ID: 28110575
[TBL] [Abstract][Full Text] [Related]
2. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
[TBL] [Abstract][Full Text] [Related]
4. [Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
Shen HJ; Wang YH; Xu J
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):98-102. PubMed ID: 23714662
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Deng L; Ren Z; Jia Q; Wu W; Shen H; Wang Y
BMC Cancer; 2013 Jul; 13():363. PubMed ID: 23895220
[TBL] [Abstract][Full Text] [Related]
6. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
7. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
8. Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-κB and Bcl-2 signaling pathways.
Xu GY; Tang XJ
Biomed Pharmacother; 2017 Aug; 92():95-107. PubMed ID: 28531805
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
10. Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
Wehler TC; Hamdi S; Maderer A; Graf C; Gockel I; Schmidtmann I; Hainz M; Berger MR; Theobald M; Galle PR; Moehler M; Schimanski CC
Int J Colorectal Dis; 2013 Mar; 28(3):385-98. PubMed ID: 22983756
[TBL] [Abstract][Full Text] [Related]
11. An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
Wang Z; Hu J; Qiu SJ; Huang XW; Dai Z; Tan CJ; Zhou J; Fan J
Expert Opin Investig Drugs; 2011 Aug; 20(8):1039-45. PubMed ID: 21671804
[TBL] [Abstract][Full Text] [Related]
12. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
[TBL] [Abstract][Full Text] [Related]
15. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
16. Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway.
Hou G; Yuan X; Li Y; Hou G; Liu X
Invest New Drugs; 2020 Apr; 38(2):329-339. PubMed ID: 31102118
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Xiao RZ; He CM; Xiong MJ; Ruan XX; Wang LL; Chen Y; Lin DJ
Oncol Rep; 2013 May; 29(5):1895-901. PubMed ID: 23467984
[TBL] [Abstract][Full Text] [Related]
19. Extract of
Cui XL; Li KJ; Ren HX; Zhang YJ; Liu XD; Bu BG; Wang L
World J Gastroenterol; 2019 Apr; 25(15):1854-1864. PubMed ID: 31057299
[TBL] [Abstract][Full Text] [Related]
20. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Yang Q; Zhang S; Kang M; Dong R; Zhao J
Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
